Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform

All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis

Excerpt from the Press Release:

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System Capsule (DDS) in Subjects with Ulcerative Colitis in a Fasted State.

The study demonstrated that the device was well tolerated, and that the device performed as intended in active ulcerative colitis (UC) patients. In all seven patients, the device accurately identified entry into the colon, triggered release of a liquid payload, and achieved distribution across the entire colon.

“Given the different gastrointestinal physiology and disease activity in patients with active ulcerative colitis, it is critical that our device can accurately identify entry into the colon, activate, and release a payload in these patients,” said Sharat Singh, PhD, Head of Research at Biora Therapeutics. “The ability to detect colon entry and deliver drug across the entire colon is potentially transformative for the management of ulcerative colitis. We are not aware of any other oral drug delivery technology that can accurately detect colon entry, especially in the environment of inflammation, bleeding, and highly variable motility seen in active ulcerative colitis,” continued Dr. Singh.

Click the button below to read the entire Press Release:

Continue Reading The Press Release